Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BIOCOTCMKTS:CBAINASDAQ:MGENOTCMKTS:POTN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBIOCBiocept$0.97$0.32▼$27.00$1.14M0.69764,067 shs751,400 shsCBAICBA Florida$0.01+1.3%$0.01$0.01▼$0.01$9.91MN/A2.73 million shs19.77 million shsMGENMiragen Therapeutics$15.67+2.9%$17.69$4.66▼$34.05$61.24M1.66134,027 shs396,663 shsPOTNUnited Treatment Centers$0.00$0.00▼$0.00N/AN/AN/A1 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBIOCBiocept0.00%0.00%0.00%0.00%0.00%CBAICBA Florida0.00%0.00%0.00%0.00%0.00%MGENMiragen Therapeutics+5.25%+3.61%+9.02%+20.40%+25.25%POTNUnited Treatment Centers0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBIOCBioceptN/AN/AN/AN/AN/AN/AN/AN/ACBAICBA FloridaN/AN/AN/AN/AN/AN/AN/AN/AMGENMiragen TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/APOTNUnited Treatment CentersN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBIOCBiocept 0.00N/AN/AN/ACBAICBA Florida 0.00N/AN/AN/AMGENMiragen Therapeutics 0.00N/AN/AN/APOTNUnited Treatment Centers 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBIOCBiocept$25.86M0.00N/AN/A$15.60 per share0.00CBAICBA FloridaN/AN/AN/AN/AN/AN/AMGENMiragen Therapeutics$4.46M13.73N/AN/A$6.78 per share2.31POTNUnited Treatment CentersN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBIOCBiocept-$32.09M-$58.45N/AN/AN/AN/A-468.87%-118.41%N/ACBAICBA Florida-$40KN/A0.00∞N/AN/AN/AN/AN/AMGENMiragen Therapeutics-$41.87M-$20.09N/AN/AN/A-1,393.50%-141.66%-88.74%N/APOTNUnited Treatment CentersN/AN/A0.00N/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBIOCBioceptN/AN/AN/AN/AN/ACBAICBA FloridaN/AN/AN/AN/AN/AMGENMiragen TherapeuticsN/AN/AN/AN/AN/APOTNUnited Treatment CentersN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBIOCBiocept2.881.811.70CBAICBA FloridaN/AN/AN/AMGENMiragen Therapeutics0.204.234.23POTNUnited Treatment CentersN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBIOCBioceptN/ACBAICBA FloridaN/AMGENMiragen TherapeuticsN/APOTNUnited Treatment CentersN/AInsider OwnershipCompanyInsider OwnershipBIOCBiocept1.61%CBAICBA Florida30.00%MGENMiragen Therapeutics1.10%POTNUnited Treatment Centers0.22%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBIOCBiocept502.63 million2.58 millionNot OptionableCBAICBA Florida21.27 billion890.45 millionNot OptionableMGENMiragen Therapeutics453.91 millionN/ANot OptionablePOTNUnited Treatment Centers13N/AN/ANot OptionablePOTN, BIOC, MGEN, and CBAI HeadlinesRecent News About These CompaniesA reader's guide for "Wellness: A novel," Oprah's book club pickSeptember 19, 2023 | msn.comNordstrom Gets the Diamond-Hands TreatmentFebruary 3, 2023 | wsj.comHead to Head Analysis: Charlie's (OTCMKTS:CHUC) & PotNetwork (OTCMKTS:POTN) - ETF Daily NewsNovember 27, 2022 | news.google.comNPotNetwork (OTCMKTS:POTN) vs. Mind Medicine (MindMed) (NASDAQ:MNMD) Critical Review - ETF Daily NewsNovember 12, 2022 | news.google.comNCBD Gummies Market Size to Hit USD 13.39 Billion by 2030; Upsurge in Demand for CBD-based Products to Bolster Growth: The Brainy Insights - Yahoo FinanceNovember 10, 2022 | news.google.comNCBD Gummies Market Size to Hit USD 13.39 Billion by 2030; Upsurge in Demand for CBD-based Products to Bolster Growth: The Brainy Insights - GlobeNewswireNovember 9, 2022 | news.google.comNBest HHC Gummies For Sale In 2022: Top 4 Hemp Brands That Sell HHC Products - KHTS RadioSeptember 13, 2022 | hometownstation.comHDIAMOND WELLNESS HOLDINGS, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K) - Marketscreener.comAugust 5, 2022 | marketscreener.comMAltcoins: Potcoin (POT) - What Is It? - A Deeper Look Into the Potcoin (POT) Platform - https://bitnewstoday.com/August 4, 2022 | bitnewstoday.comBWhat Differentiates Proof-of-Stakes and Proof-of-Time Consensus Mechanism? - The Coin RepublicJuly 26, 2022 | thecoinrepublic.comTGlobal Kid's Camera Market 2022 Industry Scenario and Demand – Vtech, Oaxis, Fujifilm, SJCAM – Indian Defence News - Indian Defence NewsJune 30, 2022 | indiandefencenews.infoIGlobal Pet CBD (cannabidiol) Market 2022 by Top Players and Vendors: ,Canna-Pet ,Choom Holdings ,Receptra Naturals ,Curaleaf ,Trulieve Cannabis ,Pure Spectrum ,Cannabis Strategies Acquisition ,Pet Releaf ,Diamond CBD ,PotNetwork Holdings ,Kat&# - Indian Defence NewsJune 30, 2022 | indiandefencenews.infoIGlobal Pet CBD (cannabidiol) Market 2022 by Top Players: ,Canna-Pet ,Choom Holdings ,Receptra Naturals ,Curaleaf ,Trulieve Cannabis ,Pure Spectrum ,Cannabis Strategies Acquisition ,Pet Releaf ,Diamond CBD ,PotNetwork Holdings ,Kat's Naturals , - mbu timelineJune 6, 2022 | mbutimeline.comMPet CBD(cannabidiol) Market Trend And Forecast| Key Players – Canna-Pet, PotNetwork Holdings, Choom Holdings, Curaleaf, Trulieve Cannabis – Industrial IT - Industrial ITMay 30, 2022 | industrialit.com.auIPOTNETWORK HOLDINGS, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K) - Marketscreener.comMay 27, 2022 | marketscreener.comMPotNetwork Holdings, Inc. (POTN) Will Change Its Name to "Diamond Wellness Holdings, Inc." - Be - BenzingaMay 26, 2022 | benzinga.comPotNetwork Holdings, Inc. (POTN) Will Change Its Name to "Diamond Wellness Holdings, Inc."May 26, 2022 | finance.yahoo.comForm DEF 14C PotNetwork Holdings, For: May 25 - StreetInsider.comMay 25, 2022 | streetinsider.comPet CBD(cannabidiol) Market by 2029 | Canna-Pet, Choom Holdings, Receptra Naturals – SMU Daily Mustang - SMU Daily MustangMay 12, 2022 | smudailymustang.comSBest THC Gummies: Top 5 Weed Brands For Buying THC Edibles & Marijuana Gummies In 2022 - The Daily WorldMay 10, 2022 | thedailyworld.comTPOTN, BIOC, MGEN, and CBAI Company DescriptionsBiocept NASDAQ:BIOCBiocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF in the United States. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, radiation oncologists, urologists, pulmonologists, pathologists, and other physicians; and clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California. On October 13, 2023, Biocept, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.CBA Florida OTCMKTS:CBAI$0.0078 +0.00 (+1.30%) As of 06/30/2020CBA Florida, Inc. does not have significant operations. Previously, the company provided private cord blood and cord tissue stem cell services. The company was formerly known as Cord Blood America, Inc. and changed its name to CBA Florida, Inc. in May 2018. CBA Florida, Inc. is based in Las Vegas, Nevada.Miragen Therapeutics NASDAQ:MGENMiragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high-unmet medical need. Its four lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous and ocular fibrosis, which is in Phase II clinical trial; MRG-229, which is in preclinical trial for the treatment of idiopathic pulmonary fibrosis; and MRG- 110, an inhibitor of miR-92, a microRNA expressed in endothelial cells, which has completed two Phase I clinical trial for the treatment of heart failure, wound healing, and other ischemic disease in the United States and Japan. Miragen Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.United Treatment Centers OTCMKTS:POTNDiamond Wellness Holdings Inc., through its subsidiaries, engages in the development and sale of hemp-derived cannabidiol (CBD) oil products. It offers flavored and unflavored oils; vaping pens and additives; edibles, such as chewable gummies and lollipops; capsules; beverage energy/relaxation shots; topical application creams in various concentrations; dog and cat wellness products in various dosages and delivery formats; skin care, bath, and body products; and hemp flowers. The company provides its products under various brands, including Diamond CBD, Chill, Relax, MediPets, and Meds BioTech, as well as various other brands. It sells its products through distributors and resellers, as well as through its Website. The company was formerly known as PotNetwork Holdings, Inc. Diamond Wellness Holdings Inc. is based in Fort Lauderdale, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
